Early detection is critical for all cancers and pancreatic cancer, like prostate cancer, does not show any symptoms until it is advanced and difficult, if not impossible, to treat effectively.
Research is continuing for a screening biomarker for pancreatic cancer that will replace the current CA 19-9 test, which has not been shown to be effective for early pancreatic cancer detection. Researchers at Queen Mary Hosptial in London are working on a urine-based early detection tool for pancreatic cancer: Queen Mary Hospital research.
It is a different situation, however, for prostate cancer, which the is most common male cancer and the number two cause of male cancer death.
Men should begin taking a prostate cancer screening test (the PSA blood test) at age 35 and then track their annual test results looking for any rising value. Men can track their PSA test values using the free ProstateTracker early detection system.
The Cancer Journeys Foundation sends it condolences and prayers to the Takai family.